This site uses cookies. By continuing to browse the site without disabling them, you consent to our use of cookies. To learn more about the types of cookies we use, please view our cookie policy.

Indivior
  • Product Query or Adverse Event
  • Careers
  • Contact Us
  • Locations
  • International
  • About
    • History
    • Leadership
  • Diseases of Addiction
    • A Worldwide Crisis
    • The Patient Journey
  • R & D
    • Publications
    • White Papers
    • Abstracts
    • Grants
  • Products
  • Responsibility
    • Environment, Climate Change and Health and Safety
    • Communities
    • Patient Safety and Product Quality
    • Corporate Integrity Agreement
    • Integrity & Compliance
    • Business Conduct
    • People
    • Advocacy and Stakeholder Engagement
    • Transparency Program
  • Investors
  • Media
  • Investor Information
    • Annual Reports
    • Press Releases
    • RNS Filings
    • RNS Filings (Inside Information)
    • SEC Filings
    • Corporate Alert Service
    • Webcasts / Audiocasts / Presentations
    • Prospectus
    • Upcoming Events
    • Buprenorphine Market Modeling Methodology
  • Share Price
    • Share Price Center
    • Share Price Table
    • Historic Share Price
    • Share Price Calculator
    • Demerger: Base Cost
  • Corporate Governance
    • UK Corporate Governance Code
    • Leadership
    • The Board
    • Board Committees
    • Executive Committees
    • Risk Management and Internal Control
    • Indivior Integrity & Compliance Program
    • Integrity & Compliance
    • Corporate Responsibility
    • Tax Strategy
    • Global Conduct Policies
  • Shareholder Information
    • Managing Your Shareholding
    • Dividends
    • Annual General Meeting
    • American Depositary Receipts
  • Contact Us
  • Investor Information
    • Annual Reports
    • Press Releases
    • RNS Filings
    • RNS Filings (Inside Information)
    • SEC Filings
    • Corporate Alert Service
    • Webcasts / Audiocasts / Presentations
    • Prospectus
    • Upcoming Events
    • Buprenorphine Market Modeling Methodology
  • Share Price Information
    • Share Price Center
    • Share Price Table
    • Historic Share Price
    • Share Price Calculator
    • Demerger: Base Cost
  • Corporate Governance
    • UK Corporate Governance Code
    • Leadership
    • The Board
    • Board Committees
    • Executive Committees
    • Risk Management and Internal Control
    • Integrity & Compliance
    • Corporate Responsibility
    • Tax Strategy
    • Global Conduct Policies
  • Shareholder Information
    • Managing Your Shareholding
    • Dividends
    • Annual General Meeting
    • American Depositary Receipts
  • Contact Us

Press Releases

View past Indivior press releases below. Press releases are sorted by date, with the most current at the top of the list.

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
12.23.2014 | PDF Version

INDIVIOR PLC Admission to the Official List and to Trading on the London Stock Exchange

11.04.2014 | PDF Version

Reckitt Benckiser Pharmaceuticals Inc. Announces Appointment Of Chief Financial Officer

10.21.2014 | PDF Version

Reckitt Benckiser Pharmaceuticals Inc. Announces Plans To Rebrand Under Indivior Plc Following Demerger

05.19.2014 | PDF Version

Reckitt Benckiser Pharmaceuticals Inc. Enters Into Agreement to Develop and Market First Naloxone Nasal Treatment for Opioid Overdose

05.15.2014 | PDF Version

Reckitt Benckiser Pharmaceuticals and XenoPort Enter Into Global Licensing Agreement for Arbaclofen Placarbil

  • About
  • Diseases of Addiction
  • R & D
  • Products
  • Responsibility
  • Investors
  • Media
  • MODERN SLAVERY STATEMENT (PDF)
  • Product Query or Adverse Event
  • Careers
  • Contact
  • Terms of Use
  • Privacy Policy
  • Accessibility
  • Privacy Policy and Notice for California Residents
  • International

© 2020 Indivior PLC | INDIVIOR is a registered trademark of Indivior UK Limited.

You are now leaving Indivior.com to visit Suboxone.com a US product site intended for US residents and healthcare professionals.

Continue    Return

You are now leaving Indivior.com.

Continue    Return

You are about to leave the Indivior website

The product specific Internet site that you have requested is intended for US audiences, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or regions.

Do you wish to continue to this product-specific site?

YES
I agree
NO
I disagree